Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)
Editas Medicine (EDIT) reported Restructuring Costs of $26.1 million for Q2 2025, down 36.16% on a QoQ basis from $40.9 million in Q1 2025.
Editas Medicine (EDIT) has 2 years of Restructuring Costs data on file, last reported at $26.1 million in Q2 2025.
- Quarterly Restructuring Costs changed N/A year-over-year to $26.1 million in Q2 2025, while the trailing twelve-month figure through Sep 2025 was $79.2 million (changed N/A YoY) and the FY2024 annual result came in at $12.2 million, changed N/A from the prior year.
- Restructuring Costs slipped to $26.1 million in Q2 2025 per EDIT's latest filing, from $40.9 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $40.9 million in Q1 2025 and bottomed at $12.2 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26.08 Mn |
| Mar 31, 2025 | 40.85 Mn |
| Dec 31, 2024 | 12.23 Mn |